Glaucoma Risk Factors and Outcomes Following Boston Keratoprosthesis Type 1 Surgery

被引:18
|
作者
Geoffrion, Dominique [1 ,2 ]
Harissi-Dagher, Mona [2 ]
机构
[1] McGill Univ, Fac Med, Dept Expt Surg, Montreal, PQ, Canada
[2] Ctr Hosp Univ Montreal CHUM, Dept Ophthalmol, 1051 Sanguinet,D-01-2273, Montreal, PQ H2X 3E4, Canada
关键词
VISUAL OUTCOMES; COMPLICATIONS; PROGRESSION; MANAGEMENT; VISION; EYES;
D O I
10.1016/j.ajo.2021.01.006
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE: To evaluate glaucoma risk factors and associated outcomes of the Boston keratoprosthesis type I (KPro). DESIGN: Clinical case-control study. METHODS: This is a single-center study of 140 eyes of 118 patients who underwent KPro surgery between October 2008 and March 2017 by a single surgeon. A total of 118 eyes of 118 patients with at least 6 months of follow-up were analyzed to account for intereye correlation. Patients without glaucoma were compared to those diagnosed with glaucoma, which included treatment with intraocular pressure (IOP)-lowering medications or glaucoma surgery. A subgroup analysis compared eyes with pre-KPro glaucoma with those with post-KPro glaucoma. Statistical analysis was performed using univariate and multivariate analyses and Kaplan-Meier survival curves. Main outcome measures were glaucoma diagnosis and progression. Other outcomes included demographics, preoperative diagnosis, best-corrected visual acuity, IOP, cup-to-disc ratio progression and postoperative complications. RESULTS: The mean age at surgery was 60.7 +/- 16.7 years, with a follow-up of 6.9 +/- 3.2 years. De novo KPro glaucoma incidence was 24% (n = 28/118), equivalent to 3.4 cases per 100 eye-years, with onset at 2.1 +/- 2.2 postoperative years. A total of 17 of 118 eyes (14%) did not have glaucoma. Multiple logistic regression showed that high preoperative IOP was a predictor of higher rates of glaucoma development (odds ratio [OR] = 1.538, 95% confidence interval [CI] = 1.030-2.297, P = .035) and progression (OR = 1.450, 95% CI = 1.084-1.937, P = .012). Stromal and endothelial disorders were protective preoperative diagnoses for glaucoma progression after KPro (OR = 0.002, 95% CI = 0.000-0.227, P = .010). A greater proportion of eyes with autoimmune and ocular surface diseases developed de novo glaucoma after KPro compared with other preoperative diagnoses (P < .05). A total of 45% of glaucomatous KPro eyes suffered postoperative glaucoma progression. The mean final best corrected visual acuity of the cohort was 1.76 +/- 1.0, with no difference between eyes with and without glaucoma (P > .05). The rate of serious vision-threatening complications was higher in KPro eyes without glaucoma (77%) than in those with glaucoma (41%, P = .006). CONCLUSIONS: High preoperative IOP signals a higher risk for glaucoma development and progression after KPro surgery. Autoimmune diseases and ocular surface diseases precipitate de novo glaucoma, whereas stromal and endothelial disorders protect against glaucoma progression after KPro. The minority of KPro eyes without glaucoma remain at high risk of complications that can hinder promising visual outcomes. Despite all available treatments and surgical interventions, a majority of eyes will suffer from glaucoma progression, even later during follow-up. ((C) 2021 Elsevier Inc. All rights reserved.)
引用
收藏
页码:56 / 67
页数:12
相关论文
共 50 条
  • [21] Glaucoma Management in Patients With Aniridia and Boston Type 1 Keratoprosthesis
    Nascimento E Silva, Rafaella
    Shen, Lucy Q.
    Chiou, Carolina A.
    Shanbhag, Swapna S.
    Paschalis, Eleftherios I.
    Pasquale, Louis R.
    Colby, Kathryn A.
    Lman, Claes H. Doh
    Chodosh, James
    Alves, Milton R.
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2019, 207 : 258 - 267
  • [22] Expected Visual Field Outcomes Following Boston Keratoprosthesis Type I and II in Eyes without Glaucoma
    Crist, Charlotte
    Dohlman, Claes H.
    Chodosh, James
    Chen, Teresa C.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (07)
  • [23] Glaucoma Associated With Boston Type I Keratoprosthesis
    Kamyar, Roheena
    Weizer, Jennifer S.
    de Paula, Fernando Heitor
    Stein, Joshua D.
    Moroi, Sayoko E.
    John, Denise
    Musch, David C.
    Mian, Shahzad I.
    CORNEA, 2012, 31 (02) : 134 - 139
  • [24] Glaucoma Progression and Role of Glaucoma Surgery in Patients With Boston Keratoprosthesis
    Crnej, Alja
    Paschalis, Eleftherios I.
    Salvador-Culla, Borja
    Tauber, Allyson
    Drnovsek-Olup, Brigita
    Shen, Lucy Q.
    Dohlman, Claes H.
    CORNEA, 2014, 33 (04) : 349 - 354
  • [25] Endophthalmitis in Eyes With the Boston Type I Keratoprosthesis: Incidence, Recurrence, Risk Factors, and Outcomes
    Bostan, Cristina
    Nayman, Taylor
    Szigiato, Andrei-Alexandru
    Morfeq, Hussein
    Harissi-Dagher, Mona
    CORNEA, 2021, 40 (10) : 1258 - 1266
  • [26] Boston type 1 keratoprosthesis outcomes in ocular burns
    Magalhaes, Fernanda Pedreira
    Hirai, Flavio Eduardo
    de Sousa, Luciene Barbosa
    de Oliveira, Lauro Augusto
    ACTA OPHTHALMOLOGICA, 2013, 91 (06) : e432 - e436
  • [27] Review of endophthalmitis following Boston keratoprosthesis type 1
    Robert, Marie-Claude
    Moussally, Krystel
    Harissi-Dagher, Mona
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2012, 96 (06) : 776 - 780
  • [28] Outcomes of Repeat Boston Type 1 Keratoprosthesis Implantation
    Ahmad, Sumayya
    Mathews, Priya M.
    Srikumaran, Divya
    Aldave, Anthony J.
    Lenis, Tamara
    Aquavella, James V.
    Hannush, Sadeer B.
    Belin, Michael
    Akpek, Esen Karamursel
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2016, 161 : 181 - 187
  • [29] Outcomes Following Boston Type 1 Keratoprosthesis Implantation in Aniridia Patients at the University of Montreal
    Hassanaly, Salima I.
    Talajic, Julia C.
    Harissi-Dagher, Mona
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2014, 158 (02) : 270 - 276
  • [30] Idiopathic Vitritis after Boston Type 1 Keratoprosthesis Implantation: Incidence, Risk Factors and Outcomes in a Multicentric Cohort
    Bonnet, Clemence
    Chehaibou, Ismael
    Ghaffari, Reza
    Jackson, Nicholas J.
    Bostan, Cristina
    Hubschman, Jean-Pierre
    Harissi-Dagher, Mona
    Aldave, Anthony J.
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2022, 30 (04) : 769 - 775